Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
46 hedge funds and large institutions have $64.1M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
51% more capital invested
Capital invested by funds: $42.4M → $64.1M (+$21.7M)
4% less funds holding
Funds holding: 48 → 46 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$634K |
| 2 |
Renaissance Technologies
New York
|
+$585K |
| 3 |
Morgan Stanley
New York
|
+$470K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$266K |
| 5 |
Squarepoint
New York
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$2.93M |
| 2 |
BlackRock
New York
|
-$1.39M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$852K |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$657K |
| 5 |
NEPWA
New England Private Wealth Advisors
Wellesley,
Massachusetts
|
-$249K |
ELOX Hedge Fund Activity: Q4 2019 in Review
46 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q4 2019, worth a combined $64.1M — up 51% from $42.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELOX and 5 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 22 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $634K. The largest seller was Clal Insurance, cutting an estimated $2.93M.
- 46 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q4 2019, down from 48 in Q3 2019.
- Funds reported $64.1M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 51% quarter-over-quarter.
- 5 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of -2 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Bridgeway Capital Management, an estimated $634K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Clal Insurance, an estimated $2.93M sold.
Based on aggregated 13F filings for Q4 2019.